Accredited eLearning

EACCME^®-accredited eLearning

Receive one (1) CME credit when you complete this interactive EACCME^®-accredited eLearning module on Biomarker innovations for Alzheimer's disease.

Course overview

This original CME module summarises evidence on three groups of biomarkers that have the potential to meet unmet needs in Alzheimer’s disease (AD), due to high specificity and sensitivity for the diagnosis of AD, and minimal invasiveness. In short video clips, Professor Henrik Zetterberg complements and extends this content. Evaluate your understanding of the module content in four quizzes.

Meet the expert

Professor Henrik Zetterberg

Henrik Zetterberg is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and leads the UK DRI Fluid Biomarker Laboratory at UCL. He is a Key Member of the Hong Kong Center for Neurodegenerative Diseases, and a Visiting Professor in the UW Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 1800 scientific articles, and received many awards.

Disclosures: served at scientific advisory boards, and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. Given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. Co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Further information

Quizzes are given at the end of each module section. There are four (4) quizzes in total. To receive your EACCME®-accredited CME certificate, and pass the module, you must achieve a score of 70% or above in each quiz.

At the end of the course, you will be requested to complete a short survey, giving you the chance to provide feedback on your experience of the module.

On completion of this course, participants will able to describe:

• The unmet needs affecting treatment of Alzheimer’s disease (AD)
• Several biomarkers for Alzheimer’s disease
• The role of biomarkers in the development of AD
• The relationship of biomarkers with various aspects of AD
• Problems and challenges in the search for AD biomarkers
• Recommendations that could facilitate the development of new diagnostic biomarkers for AD